


Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

RCE/1628  
D/JM

**Request  
for  
Continued Examination (RCE)  
Transmittal**

Address to:  
Mail Stop RCE  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450



Application Number	10/718,403
Filing Date	11/20/2003
First Named Inventor	Steffen BREITFELDER
Art Unit	1625
Examiner Name	Evelyn Mei HUANG
Attorney Docket Number	1/1423

This is a Request for Continued Examination (RCE) under 37 CFR 1.114 of the above-identified application.

Request for Continued Examination (RCE) practice under 37 CFR 1.114 does not apply to any utility or plant application filed prior to June 8, 1995, or to any design application. See Instruction Sheet for RCEs (not to be submitted to the USPTO) on page 2.

1. **Submission required under 37 CFR 1.114** Note: If the RCE is proper, any previously filed unentered amendments and amendments enclosed with the RCE will be entered in the order in which they were filed unless applicant instructs otherwise. If applicant does not wish to have any previously filed unentered amendment(s) entered, applicant must request non-entry of such amendment(s).

- a.  Previously submitted. If a final Office action is outstanding, any amendments filed after the final Office action may be considered as a submission even if this box is not checked.

- i.  Consider the arguments in the Appeal Brief or Reply Brief previously filed on \_\_\_\_\_  
ii.  Other \_\_\_\_\_

- b.  Enclosed

- |   |   |
|---|---|
| i. <input type="checkbox"/> Amendment/Reply               | iii. <input checked="" type="checkbox"/> Information Disclosure Statement (IDS) |
| ii. <input type="checkbox"/> Affidavit(s)/ Declaration(s) | iv. <input type="checkbox"/> Other _____  |

2. **Miscellaneous**

- a.  Suspension of action on the above-identified application is requested under 37 CFR 1.103(c) for a

period of \_\_\_\_\_ months. (Period of suspension shall not exceed 3 months; Fee under 37 CFR 1.17(i) required)

- b.  Other \_\_\_\_\_

3. **Fees** The RCE fee under 37 CFR 1.17(e) is required by 37 CFR 1.114 when the RCE is filed.

- a.  The Director is hereby authorized to charge the following fees, or credit any overpayments, to Deposit Account No. 02-2955. I have enclosed a duplicate copy of this sheet.

- i.  RCE fee required under 37 CFR 1.17(e)  
ii.  Extension of time fee (37 CFR 1.136 and 1.17)  
iii.  Other \_\_\_\_\_

- b.  Check in the amount of \$ \_\_\_\_\_ enclosed

- c.  Payment by credit card (Form PTO-2038 enclosed)

**WARNING:** Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

**SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT REQUIRED**

Signature		Date	01/04/2005
Name (Print/Type)	Andrea D. Small	Registration No.	54,859

**CERTIFICATE OF MAILING OR TRANSMISSION**

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Mail Stop RCE, Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450 or facsimile transmitted to the U.S. Patent and Trademark Office on the date shown below.


Signature		Date	01/04/2005
Name (Print/Type)	Andrea D. Small	Registration No.	54,859

This collection of information is required by 37 CFR 1.114. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Mail Stop RCE, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

01/10/2005 FMEKEI1 0000009 022955 10718403

01 FC:1801 790.00 DA



THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of : Breitfelder, S. et al ) Art Unit: 1625  
Serial No. : 10/718,403 ) Examiner: Evelyn Mei HUANG  
Confirmation No. : 9746  
Filed : 11/20/2003  
For : Carbamic Acid Esters with Anticholinergic Activity  
Docket No. : 1/1423

Mail Stop RCE  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

I hereby certify that this correspondence is being deposited with the U.S. Postal Service as first class mail in an envelope addressed to:

Mail Stop RCE  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

on January 4, 2005.

*A. Small*  
By: Andrea D. Small  
Reg. No. 54,859

**REQUEST FOR CONTINUED EXAMINATION**

Dear Sir:

In response to the Notice of Allowability mailed December 23, 2004, applicants herewith file a Request for Continued Examination under 37 CFR 1.114(a)(1) and 37 CFR 1.114(c) and an Information Disclosure Statement citing art and copending applications for consideration by the Examiner.

Applicants respectfully request that the Examiner in the next Office Action confirm that:

- (1) that the art cited in the IDS has been considered.

Applicants also wish to express their gratitude to the Examiner for his efforts in assisting applicants throughout this prosecution.

AMENDMENT  
U.S. Appln. No.

As a last matter, applicants respectfully request that the Examiner ensure that the above application be expeditiously brought to issue. Please advise me immediately if you require anything further.

Respectfully submitted,

*adsmall*  
Andrea D. Small  
Attorney for Applicant(s)  
Reg. No. 54,859

Patent Department  
Boehringer Ingelheim Corp.  
900 Ridgebury Road  
P.O. Box 368  
Ridgefield, CT. 06877  
Tel.: (203) 798-4816  
Fax: (203) 798-4408